Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 14/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.65 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278433 | 0.87 | ITGB1 (0.68) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL13601967 | 0.86 | ITGB1 (0.74) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL13602029 | 0.84 | ITGB1 (0.74) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL13601958 | 0.81 | ITGB1 (0.76) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL21891858 | 0.80 | PPID (0.52) | — | |
| SCHEMBL8278429 | 0.79 | ITGB1 (1.00) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL8280286 | 0.78 | ITGB1 (0.66) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL2327300 | 0.78 | KMT2A (0.60) | KMT2A | |
| SCHEMBL2327298 | 0.78 | KMT2A (0.60) | KMT2A | |
| SCHEMBL8297110 | 0.78 | ITGB1 (0.59) | ITGB1ITGA4ITGB7ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | ITGB1 7/4885ITGA4 4/4885ITGB7 46/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | ITGB1 8/4885ITGA4 25/4885ITGB7 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.